Bradley J. Bolzon PhD - Jun 23, 2021 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Director, 10%+ Owner
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Jun 23, 2021
Transactions value $
$0
Form type
3
Date filed
6/23/2021, 08:47 PM
Previous filing
Jun 22, 2021
Next filing
Jun 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GLUE Common Stock 283K Jun 23, 2021 By Versant Venture Capital VI, L.P.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLUE Series A convertible preferred stock Jun 23, 2021 Common Stock 5.67M By Versant Venture Capital VI, L.P. F1, F2
holding GLUE Series B convertible preferred stock Jun 23, 2021 Common Stock 850K By Versant Venture Capital VI, L.P. F1, F2
holding GLUE Series B convertible preferred stock Jun 23, 2021 Common Stock 1.18M By Versant Vantage I, L.P. F2, F3
holding GLUE Series C convertible preferred stock Jun 23, 2021 Common Stock 765K By Versant Vantage I, L.P. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F2 Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
F3 Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney